Name :
GOLPH3 antibody
Documents :
DataSheet Material Safety Data Sheets (MSDS)
Description :
GOLPH3 Rabbit Polyclonal antibody. Positive WB detected in HeLa cells, mouse lung tissue, mouse testis tissue, rat testis tissue. Positive IP detected in mouse testis tissue. Positive IF detected in HepG2 cells. Positive IHC detected in human placenta tissue, human colon cancer tissue, human colon tissue. Observed molecular weight by Western-blot: 34 kDa
Tested applications :
ELISA, WB, IHC, IF, IP
Species reactivity :
Human,Mouse,Rat; other species not tested.
Alternative names :
Coat protein GPP34 antibody; FLJ90675 antibody; Golgi phosphoprotein 3 antibody; GOLPH3 antibody; GOPP1 antibody; GPP34 antibody; MIDAS antibody
Immunogen :
Human GOLPH3 Recombinant protein (His tag)
Isotype :
Rabbit IgG
Preparation :
This antibody was obtained by immunization of GOLPH3 recombinant protein (Accession Number: NM_022130). Purification method: Antigen affinity purified.
Clonality :
Polyclonal
Formulation :
PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage instructions :
Store at -20℃. DO NOT ALIQUOT
Applications :
Recommended Dilution: WB: 1:500-1:5000IP: 1:500-1:5000IHC: 1:20-1:200IF: 1:10-1:100
Background :
GOLPH3 (also called GPP34, GMx33, MIDAS, or yeast Vps74p) is a 34-kDa Golgi-associated protein conserved from yeast to human. GOLPH3 binds to PtdIns(4)P-rich trans-Golgi membranes and MYO18A conveying a tensile force required for efficient tubule and vesicle formation (PMID: 19837035). GOLPH3 has been recently demonstrated as a novel oncoprotein amplified in various types of human malignancies, including melanoma, breast, non-small cell lung cancer, gliomas and connective tissue tumors (PMID:19553991; 23006319; 21499727; 22745132). Enhanced activation of mTOR signalling represents a molecular basis for the oncogenic activity of GOLPH3 (PMID: 19553991).
References :
Wang Z, Jiang B, Chen L. GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy. Journal of translational medicine. 12:15. 2014. Xue Y, Wu G, Liao Y. GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma. British journal of cancer. 110(9):2250-60. 2014. Zhang Y, Ma M, Han B. GOLPH3 high expression predicts poor prognosis in patients with resected non-small cell lung cancer: an immunohistochemical analysis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 35(11):10833-9. 2014. Hua X, Yu L, Pan W. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagnostic pathology. 7:127. 2012. Hu BS, Hu H, Zhu CY, Gu YL, Li JP. Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 34(1):515-20. 2013.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Phospho-Glycogen synthase 1 (S641) Antibody
Phospho-Chk2 (Thr68) Antibody
